Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

Can Ozempic and similar drugs cause muscle and bone loss? Discover how to maintain your health while achieving weight loss ...

As the New Year approaches, many of us feel refreshed and motivated to be our best. Whether you want to adopt a healthier lifestyle, set new fitness goals or just improve overall your well-being ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025.